Fig. 4From: The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis of the safety outcomes under anti-amyloid-β monoclonal antibodies in patients with AD. Forest plot of comparisons between drugs and placebo on ARIA-E (a) and ARIA-H (b)Back to article page